Important ovarian cancer data are ahead for Immunogen and Mersana, while Disc Medicine eyes a rare metabolic disorder.
The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.
Positive data result in positive share price movements – something of a novelty in the current market.
Evaluate Vantage's coverage of the Ash 2021 congress.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Amid cautionary tales of other highly valued unpartnered assets, efgartigimod approaches its US date with destiny.
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.